Clinical Trial Update: Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating IV CR845 (pts) for moderate-to-severe uremic pruritus in hemodialysis patients has completed and results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Uremic Pruritus

Drugs mentioned

• CR845 (IV)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Uremic Pruritus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-07-29